Fulcrum Therapeutics stock saw an increase following the announcement of a merger deal with Slate Medicines, aiming to develop next-generation migraine therapies, signaling positive investor reaction to the corporate development.

Slate Medicines has announced the appointment of Mark W. Hahn to its Board of Directors.